Keros Therapeutics (KROS) Net Equity Issued and Repurchased (2020 - 2025)

Keros Therapeutics (KROS) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $72.9 million in Q4 2024.

• Quarterly Net Equity Issued and Repurchased rose 6.4% year-over-year to $72.9 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $72.9 million (down 67.48% YoY) and the FY2024 annual result came in at $228.6 million, up 30.02% from the prior year.
• Net Equity Issued and Repurchased advanced to $72.9 million in Q4 2024, from $4.4 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $151.3 million in Q1 2024 to a low of -$58.2 million in Q4 2022.
• A 5-year average of $48.9 million and a median of $52.2 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased plunged 306.51% — and 2023, when it jumped 217.77%.
• Tracing KROS's Net Equity Issued and Repurchased over 5 years: stood at $56.0 million in 2020, then sank by 49.69% to $28.2 million in 2021, then sank by 306.51% to -$58.2 million in 2022, then jumped by 217.77% to $68.5 million in 2023, then advanced by 6.4% to $72.9 million in 2024.
• The last three Net Equity Issued and Repurchased figures came in at $72.9 million (Q4 2024), $4.4 million (Q3 2024), and $151.3 million (Q1 2024), per Business Quant data.